Drug Profile


Alternative Names: Trimethobenzamide/diphenhydramine

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Multi-Corp International
  • Developer Compass Point Research; NDA Partners
  • Class Antiallergics; Antiemetics; Antimigraines; Antipruritics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Migraine

Most Recent Events

  • 21 Jan 2016 MultiCorp International receives detailed response letter from the FDA for development of diphenhydramine/trimethobenzamide in Migraine
  • 08 Apr 2015 MultiCorp International collaborates with Compass Point and NDA Partners to develop diphenhydramine/trimethobenzamide for the treatment of migraine
  • 08 Apr 2015 Early research in Migraine in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top